Industry
Biotechnology
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Loading...
Open
10.66
Mkt cap
902M
Volume
656K
High
10.97
P/E Ratio
-6.85
52-wk high
16.99
Low
10.61
Div yield
N/A
52-wk low
6.06
Portfolio Pulse from Benzinga Newsdesk
September 11, 2024 | 2:36 pm
Portfolio Pulse from Benzinga Newsdesk
September 11, 2024 | 12:29 pm
Portfolio Pulse from Benzinga Newsdesk
August 23, 2024 | 11:17 am
Portfolio Pulse from Benzinga Newsdesk
August 22, 2024 | 4:02 pm
Portfolio Pulse from Benzinga Newsdesk
August 22, 2024 | 10:05 am
Portfolio Pulse from Avi Kapoor
August 21, 2024 | 1:23 pm
Portfolio Pulse from Avi Kapoor
August 20, 2024 | 12:15 pm
Portfolio Pulse from Avi Kapoor
August 20, 2024 | 11:53 am
Portfolio Pulse from Benzinga Newsdesk
August 20, 2024 | 11:47 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.